Advertisement
Zai Lab Limited (9688.HK)
HKSE - HKSE Delayed Price. Currency in HKD
Follow
At close: 04:08PM HKT
| Previous Close | 21.300 |
| Open | 21.600 |
| Bid | 21.950 x N/A |
| Ask | 22.000 x N/A |
| Day's Range | 21.600 - 22.500 |
| 52 Week Range | 10.560 - 25.800 |
| Volume | |
| Avg. Volume | 4,097,595 |
| Market Cap | 23.586B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.180 |
| Earnings Date | Feb 25, 2025 - Mar 03, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.70 |
Pharmaceutical TechnologyZai Lab and Pfizer to commercialise XACDURO in China
Pfizer's affiliated companies have exclusive rights to undertake commercialisation activities for the drug.
Business WireZai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass., November 21, 2024--Zai Lab ("Zai Lab", NASDAQ: ZLAB; HKEX: 9688) and Pfizer ("Pfizer", NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for XACDURO® in mainland China. Through this collaboration, Zai Lab will leverage the industry-leading commercialization in
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.